Distinct SARS-CoV-2 sensing pathways in pDCs driving TLR7-antiviral vs. TLR2-immunopathological responses in COVID-19Renée M. van der Sluis, Martin R. Jakobsen, Jacob Thyrsted et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 2
442-E A novel targeted, type I interferon producing, innate lymphocyte therapy with potent anti-tumor activityAnders Laustsen, Martin R. Jakobsen, Tobias Wang Bjerg et al.|Unknown|2023Cited by 0
417 Design of programmable immune reactive cells (PIRCs) with precision type I interferon and cytotoxicity response in solid tumorsAnders Laustsen, Martin R. Jakobsen, Trine I. Jensen et al.|Regular and Young Investigator Award Abstracts|2024Cited by 0
Abstract 5861: Characterizing an immune synapse between plasmacytoid dendritic cells and cancer cells that drives cancer cytotoxicityTobias Wang Bjerg, Martin R. Jakobsen, Ian Helstrup Nielsen et al.|Cancer Research|2025Cited by 0
Restoring STING expression in soft tissue sarcoma increases activation and function of tumor-infiltrating lymphocytesStine Høvring Godsk, Martin R. Jakobsen, Mireia Crus De los Santos et al.|Cancer Immunology Immunotherapy|2026Cited by 0